Post hoc analysis of the GATHER1 and GATHER2 pivotal studies has shown that treatment with Izervay (Astellas) reduced the risk of progressing to loss
A new app - Estermate - is now available for optometrists and ophthalmologists who regularly perform Esterman testing.
A completely new drug candidate – called a small molecule ‘photoswitch’ – has moved into a Phase 2 trial after a successful first-in-human trial
New research suggests that measuring biological ageing could enable clinicians to identify patients at elevated risk of cataracts before significant vision loss occurs, potentially
DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.
